Researchers from The University of Texas MD Anderson Cancer Center presented encouraging findings today from two clinical trials in a plenary session highlighting advances in novel immunotherapy approaches at the American Association for Cancer Research (AACR) Annual Meeting 2024.
A pilot study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that for people with borderline resectable pancreatic cancer, administrating an immunotherapy drug in combination with chemotherapy before surgery is safe and may improve long-term outcomes.
SEATTLE — April 3, 2024 — Below are summaries of recent Fred Hutchinson Cancer Center research findings, patient stories and other news. If you’re covering the American Association for Cancer Research (AACR) Annual Meeting, please see our list of and contact to set up interviews.
The Wilmer Eye Institute, Johns Hopkins Medicine has received two awards totaling more than $20 million from the National Eye Institute at the National Institutes of Health, both of which will be used for a six-year clinical trial investigating a potential treatment for the most common inherited retinal disease, retinitis pigmentosa.
Curtis L. Cetrulo Jr., MD, vice chair of Research in the Department of Surgery and director of the Division of Plastic Surgery, has been selected as the General William and Willa Dean Lyon Family Chair in Reconstructive and Plastic Surgery.
Researchers from Fred Hutchinson Cancer Center, the American Cancer Society Cancer Action Network and peer institutions released new findings in the Journal of Clinical Oncology showing that when all types of cancer research studies are considered, at least one in five people with cancer in the U.S., or 21.9%, participate in some form of clinical research.
The five-day session (April 5-10), themed as “Inspiring Science. Fueling Progress. Revolutionizing Care,” will include new findings from Yale Cancer Center researchers.
A 'Comprehensive Cancer Center' is the top U.S. designation for cancer research and treatment facilities recognized by high-quality research that leads to major shifts in cancer care.
A clinical trial from Keck Medicine of USC will test the feasibility of treating non-small cell lung cancer with immunotherapy provided at home.
A pair of medications that make malignant cells act as if they have a virus could hold new promise for treating colorectal cancers and other solid tumors, reports a study published today in Science Advances.
A gene therapy developed by researchers at UT Southwestern Medical Center for a rare disease called giant axonal neuropathy (GAN) was well tolerated in pediatric patients and showed clear benefits, a new study reports. Findings from the phase one clinical trial, published in the New England Journal of Medicine, could offer hope for patients with this rare condition and a host of other neurological diseases.
UCI Health, the clinical enterprise of the University of California, Irvine, has completed the acquisition of four hospitals and associated outpatient locations from Tenet Healthcare Corporation.
Mariam F. Eskander, MD, MPH, surgical oncologist in the Gastrointestinal Oncology Program at Rutgers Institute of New Jersey, offers insight and tips for minority individuals navigating a cancer diagnosis and how we can all work together to mitigate cancer disparities.
Head and neck cancer is the term used to describe a number of different malignant tumors that develop in or around the throat, larynx, nose, sinuses and mouth.
For years, it was harder for Black patients to secure a coveted spot on the national kidney transplant waitlist because a clinical algorithm was making Black patients appear healthier than they were.
The drug minocycline, an antibiotic that also decreases inflammation, failed to slow vision loss or expansion of geographic atrophy in people with dry age-related macular degeneration (AMD), according to a phase II clinical study at the National Eye Institute (NEI), part of the National Institutes of Health.
ScienceMedia, a global SaaS provider redefining the landscape of clinical mastery in the biotech and pharma industries, announces the formation of its inaugural advisory board.
A new treatment approach that combines a targeted therapy drug with hormone therapy significantly increased the amount of time a person with stage 2 or 3 HR-positive, HER2-negative early breast cancer lives without the cancer returning, according to a new study co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators.
The ATS 2024 International Conference Program is now live! Get ready for a series of dynamic scientific programming with presentations covering AI in thoracic medicine, the basic sciences, research breakthroughs and clinical treatment, as well as spotlighting the next generation of innovators in pulmonary, critical care and sleep medicine.
In the first clinical trial of a targeted pharmacologic therapeutic for mild traumatic brain injury in pediatric patients, scientists have found preliminary evidence that adolescents and young adults with concussion who take a specific formulation of branched chain amino acid (BCAA) supplements after injury experience faster symptom reduction and return to physical activity.
Scientists at St. Jude Children’s Research Hospital have uncovered a metabolic role for cell-survival protein MCL-1, potentially explaining previous clinical trial setbacks.
20240208171546.png&width=400&height=400)
A team at Memorial Sloan Kettering Cancer Center (MSK) led by thoracic surgeon Prasad Adusumilli, MD, has been awarded a distinguished UG3/UH3 grant from the National Cancer Institute (NCI) to advance research and testing of chimeric antigen receptor (CAR) T cell therapy for solid tumors.
New Cleveland Clinic-led research provides evidence that video laryngoscopy significantly decreased the number of attempts needed to achieve intubation in adult surgical patients who required single-lumen endotracheal intubation for general anesthesia, compared with direct laryngoscopy. The research was published today in JAMA.
St. Baldrick’s Foundation Awards $50,000 Grant to Expand Pediatric Cancer Clinical Trials at K. Hovnanian Children’s Hospital
Resmetirom (Rezdiffra) is the first drug approved for treating MASH, an advanced form of fatty liver disease. UChicago Medicine experts contributed to a recent clinical trial and will begin incorporating the drug into liver disease treatment regimens for eligible patients.
Omeza®, a regenerative skincare company that develops marine-based therapies for the treatment of chronic wounds, today presented positive interim data from a diabetic foot ulcer (DFU) clinical trial showing that Omeza® OCM™ plus offloading of weight on the affected foot achieved a 91 percent area reduction (PAR) rate in DFUs within twelve weeks, and a 63 percent PAR within four weeks.
A clinical trial from Keck Medicine of USC aims to provide a surgical solution for patients with a form of advanced pancreatic cancer previously considered inoperable.
“This is the largest annual research budget in our 46-year history,” said Thomas M. Brunner, GRF President and CEO.
A high impact study led by Daniel Spratt, MD, Vincent K. Smith Chair in Radiation Oncology at University Hospitals Seidman Cancer Center demonstrates the safety and efficacy of a novel oral hormone therapy, relugolix, in conjunction with radiation therapy for treating men with localized and advanced prostate cancer. This work is published in JAMA Oncology.
The Phase 3 CELLEBRATE trial to test a regenerative stem cell-based therapy in treating patients with stress urinary incontinence is continuing to recruit additional subjects after changing its study protocol to include only patients who have already tried surgery.
In the largest randomized clinical trial and first of its kind to date in the United States, a team led by investigators at Beth Israel Deaconess Medical Center (BIDMC) assessed the efficacy and safety of using a drug-coated balloon in patients undergoing coronary angioplasty.
The Smidt Heart Institute at Cedars-Sinai recently became one of four institutions in the U.S. and the first on the West Coast to use a new device aimed at lowering blood pressure in patients with difficult-to-treat hypertension.
An injectable hydrogel can mitigate damage to the right ventricle of the heart with chronic pressure overload, according to a new study published March 6 in Journals of the American College of Cardiology: Basic to Translational Science. The study, by a research team from the University of California San Diego, Georgia Institute of Technology and Emory University, was conducted in rodents.
Below are summaries of recent Fred Hutchinson Cancer Center research findings and other news. March is Colorectal Cancer Awareness Month, contact our media team to set up interviews.
Health researchers at The University of Texas at El Paso are launching a clinical trial to improve walking in the El Paso community, thanks to a $4.4 million grant from the National Institutes of Health. The project will enroll local school district employees in 50K 4 Life, a program that challenges them to improve their health by walking at least 50,000 steps per week.
Over the past decade, the advent of new medications has been a game changer for many children and adults with cystic fibrosis (CF). But while these therapies can significantly enhance lung function, they are not a cure—and not all patients are eligible for them. At Children’s Hospital Los Angeles, the Cystic Fibrosis Center is dedicated to improving the lives of all children with CF.
New research shows HIV medications can be taken at the same time as hormone treatment without losing potency of either therapy.
Experts at Rogel Cancer Center develop and study the impact of a new drug for salivary gland cancers
In a first-of-its-kind study published in the American Journal of Respiratory and Critical Care Medicine, physician-scientists from the University of Alabama at Birmingham Marnix E. Heersink School of Medicine discovered that high-dose inhaled nitric oxide therapy may improve oxygenation and reduce the risk of mortality among critically ill Black patients with COVID-19.
The FDA has approved two medications for the treatment of eosinophilic esophagitis (EoE)—the first oral medication tailored for adults and the exclusive therapeutic option for children. Evan Dellon, MD, MPH, internationally known for his work with EoE, and colleagues continue to focus on optimizing usage for effective, personalized outcomes.
In an early phase clinical trial, a combination of antibody-based medications targeting the immune system generated promising safety data and anti-tumor activity in individuals with various types of advanced cancer.
Neuroscientist Emily Rogalski, PhD, is a principal investigator on a grant from the NIH to support a clinical trial of a telehealth intervention for primary progressive aphasia (PPA).
Pulmonary diseases across all ages threaten millions of people and have emerged as one of the major public health issues worldwide. For diverse disease conditions, the currently available approaches are focused on alleviating clinical sympt
Children’s Healthcare of Atlanta and Emory University participated in a nationwide clinical trial showing that a 16-week course of omalizumab, an injectable drug, increased the amount of peanut, tree nuts, egg, milk and wheat that some multi-food allergic children as young as one year could consume without an allergic reaction after exposure.
.jpg&width=400&height=400)
An international team, including researchers from McMaster University and St. Joseph’s Healthcare Hamilton, has identified a new therapeutic for patients with a rare autoimmune disease called eosinophilic granulomatosis with polyangiitis (EGPA). A biologic drug called benralizumab has been shown to be non-inferior to mepolizumab in the treatment of EGPA.
Samara Rahman, 74, enrolled in a clinical trial at UCLA Health that was evaluating an “off-the-shelf” vaccine that is given after surgery to prevent or delay the cancer from coming back in high-risk patients.
PolyBio Research Foundation today announced the second phase of its LongCovid Research Consortium (LCRC), including the distribution of $15M to fund research and clinical trials.
UNC Lineberger Comprehensive Cancer Center has been selected as one of nine national research sites for the National Cancer Institute’s newly launched Cancer Screening Research Network, which will evaluate promising and emerging cancer screening technologies.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
